Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 14, 2017; 23(42): 7495-7504
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495
Published online Nov 14, 2017. doi: 10.3748/wjg.v23.i42.7495
Figure 1 Current and emerging drugs for non- alcoholic fatty liver disease and their mechanism of action.
PPAR: Peroxisome proliferator-activated receptor; SCD1: Stearoyl CoA desaturase-1; FXR: Farnesoid X receptor.
- Citation: Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504
- URL: https://www.wjgnet.com/1007-9327/full/v23/i42/7495.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i42.7495